Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Impact · against what's priced in

The long-term Phase 3 data for TransCon PTH confirms the drug's sustained efficacy and safety over 182 weeks, reducing clinical risk for Ascendis Pharma. The ability to eliminate the need for conventional vitamin D and calcium supplements enhances the drug's competitive profile and commercial potential.

ASND+0.60

No priced-in read yet